相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Neuland Laboratories has entered a development partnership with LIR Life Sciences to advance cell-penetrating peptide technology for transdermal GLP-1/GIP obesity therapies. - The collaboration will support pharmacokinetic and pharmacodynamic studies as well as Phase I formulations for LIR Life's patch-based delivery system. - This represents a potentially significant innovation as there are currently no approved transdermal GLP-1 therapies on the market. - Neuland has invested $50 million in peptide infrastructure, including a new facility with 6,370 litres of capacity expected to be operational by mid-2026.
- Neuland Laboratories has announced the appointment of a new Chief Executive Officer and Managing Director as of December 8, 2025. - The leadership transition marks a significant corporate development for the India-based pharmaceutical and active pharmaceutical ingredient manufacturer. - The announcement was reported by Process Worldwide, a publication covering the pharmaceutical and chemical processing industries.
- Gujarat-based Allchem Lifescience has filed preliminary IPO papers with SEBI, seeking to raise ₹190 crore through fresh equity shares and an offer for sale of 71.55 lakh shares by promoters. - The company specializes in manufacturing API intermediates and piperazine derivatives critical for drugs like quetiapine, with ₹130 crore of proceeds earmarked for debt repayment. - Allchem has demonstrated strong financial growth with revenue CAGR of 12.75% and profit CAGR of 28.65% between FY22-24, serving 214 customers across 22 countries globally.
